ARV-Trials.com

Head-to-head comparative trials for first line ART since 2006

NRTI combinations

NNRTI vs NNRTI

EFV 600 + FTC/TDF vs EFV 400 + FTC/TDF

ENCORE1 Study: (EFV 400 mg vs 600 mg QD) + TDF/FTC
Encore1 Study Group Lancet. 2014 Apr 26;383(9927):1474-82 & Lancet Infect Dis 2015;15:793-802

EFV + FTC/TDF or 2 NRTI vs RPV + FTC/TDF or 2 NRTI

THRIVE Study: RPV + 2 NRTI vs EFV + 2 NRTI ; ECHO & THRIVE Study: W96 results
Molina JM. Lancet. 2011 Jul 16;378(9787):238-46 ; Cohen CJ. Lancet. 2011 Jul 16;378(9787):229-37 & AIDS. 2013 Mar 27;27(6):939-50 ; Rimsky L. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):39-46 & Antivir Ther. 2013;18(8):967-77

RPV/FTC/TDF vs EFV/FTC/TDF

STAR Study: RPV/FTC/TDF vs EFV/FTC/TDF
Cohen C. AIDS 2014;28:989-97 ; Porter DP. HIV Clin Trials 2015;16:30-8 ; Van Lunzen J. AIDS 2016;30:251-9

EFV + 2 NRTI vs ETR + 2 NRTI

SENSE Study: ETR QD + 2 NRTI vs EFV QD + 2 NRTI
Gazzard B. AIDS. 2011 Nov 28;25(18):2249-58 ; Nelson M. AIDS. 2011 Jan 28;25(3):335-40

EFV/FTC/TDF vs DOR/3TC/TDF

DRIVE-AHEAD Study: DOR/3TC/TDF vs EFV/FTC/TDF
Orkin C. Clin Infect Dis. 2019 ;68:535-44

NNRTI vs PI/r

EFV + 2 NRTI vs LPV/r + 2NRTI vs EFV + LPV/r

Study ACTG A5142: [(EFV vs LPV/r) + 2 NRTIs] vs EFV + LPV/r
Riddler SA. N Engl J Med. 2008 May 15;358(20):2095-106

EFV + ZDV/3TC vs LPV/r + ZDV/3TC

Study Mexican: EFV vs LPV/r, in combination with ZDV/3TC
Sierra-Madero J. J Acquir Immune Defic Syndr. 2010 Apr;53(5):582-8

NVP + FTC/TDF vs ATV/r + FTC/TDF

Study ARTEN : [NVP (QD or BID) vs ATV/r] + TDF/FTC
Soriano V. Antivir Ther. 2011;16(3):339-48 ; Podzamczer D. HIV Med. 2011 Jul;12(6):374-82

ABC/3TC + EFV or ATV/r vs FTC/TDF + EFV or ATV/r

Study ACTG A5202 : ABC/3TC vs TDF/FTC
Sax PE. N Engl J Med. 2009 Dec 3;361(23):2230-40 ; Daar ES. CROI 2010. Abs. 59LB

DOR + 2 NRTI vs DRV/r + 2 NRTI

DRIVE-FORWARD Study: DOR + 2 NRTI vs DRV/r + 2 NRTI
Molina JM, Lancet HIV 2018;5:e211-20 ; Molina JM, IAC 2018, Abs. LBPEB017

EFV vs MVC

EFV + ZDV/3TC vs MVC + ZDV/3TC

MERIT Study: maraviroc vs efavirenz, in combination with ZDV/3TC
Cooper DA. J Infect Dis. 2010 Mar 15;201(6):803-13

PI vs PI

ATV + 3TC + d4T vs ATV/r + 3TC + d4T

Study BMS 089: ATV vs ATV/r QD, in combination with 3TC + d4T XR QD
Malan DR. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):161-7

LPV/r mono vs LPV/r + ZDV/3TC

MONARK Study: LPV/r BID monotherapy vs LPV/r BID + ZDV/3TC
Delfraissy JF. AIDS. 2008 Jan 30;22(3):385-93

LPV/r QD + FTC + TDF vs LPV/r BID + FTC + TDF

Study M02-418: LPV/r QD vs BID, in combination with TDF + FTC
Johnson MA. J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):153-60

Study M05-730: LPV/r QD vs BID, in combination with TDF + FTC QD
Gathe J. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):474-81

LPV/r QD + FTC + d4T or TDF vs LPV/r BID + FTC + d4T or TDF

Study ACTG A5073: LPV/r QD vs BID, in combination with FTC + (d4T-XR or TDF)
Flexner C. Clin Infect Dis. 2010 Apr 1;50(7):1041-52

ATV/r + FTC/TDF vs FPV/r + FTC/TDF

ALERT Study: ATV/r QD vs FPV/r QD, in combination with TDF/FTC
Smith KY. AIDS Res Ther. 2008 Mar 28;5:5

ATV/r + FTC/TDF vs DRV/r + FTC/TDF

ATADAR Study: ATV/r + TDF/FTC vs DRV/r + TDF/FTC
Martinez E. CID 2015;60:811-20 ; Saumoy M. J AntimicrobChemother 2015;70:1130-8

FPV/r + ABC/3TC vs LPV/r + ABC/3TC

KLEAN Study: FPV/r BID vs LPV/r BID, in combination with ABC/3TC
Eron JJ. Lancet. 2006 Aug 5;368(9534):476-82

SQV/r + FTC/TDF vs LPV/r + FTC/TDF

GEMINI Study: SQV/r BID vs LPV/r BID, in combination with TDF/FTC
Walmsley S. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):367-74

ATV/r + FTC/TDF vs LPV/r + FTC/TDF

CASTLE Study: ATV/r QD vs LPV/r BID, in combination with TDF/FTC
Molina JM. Lancet. 2008 Aug 23;372(9639):646-55; J Acquir Immune Defic Syndr. 2010 Mar;53(3):323-32

DRV/r + FTC/TDF vs LPV/r + FTC/TDF

ARTEMIS Study: DRV/r QD vs LPV/r (BID or QD),in combination with TDF/FTC
Ortiz R. AIDS. 2008 Jul 31;22(12):1389-97 ; Mills AM. AIDS. 2009 Aug 24;23(13):1679-88 ; Orkin C. HIV Med. 2013 Jan;14(1):49-59

DRV/r + 3TC vs DRV/r + 3TC/TDF

ANDES Study: DRV/r + 3TC vs DRV/r + 3TC/TDF
Figueroa MI CROI 2018, Abs. 489

RTV vs Cobi

ATV/r + FTC/TDF vs ATV/c + FTC/TDF

Study GS-US-216-0114: ATV + ritonavir + FTC/TDF QD vs ATV + cobicistat + FTC/TDF
Gallant JE. J Infect Dis. 2013 Jul;208(1):32-9; J Acquir Immune Defic Syndr . 2015 Jul 1; 69 (3): 338-40

INSTI vs INSTI

RAL QD + FTC/TDF vs RAL BID + FTC/TDF

QDMRK Study: raltegravir QD vs BID, with TDF/FTC
Eron JJ. Lancet Infect Dis. 2011 Dec;11(12):907-15

DTG QD + 2 NRTI vs RAL BID + 2 NRTI

SPRING-2 Study: DTG QD + 2 NRTI vs RAL BID + 2 NRTI
Raffi F. Lancet. 2013 Mar 2;381(9868):735-43; Lancet Infect Dis. 2013 Nov;13(11):927-35

RAL 1200 QD vs 400 BID + FTC/TDF

ONCEMRK Study: raltegravir 1200 mg QD vs 400 mg BID, with TDF/FTC
Cahn P. Lancet HIV, 2017;4:e486-94 ; Cahn P, JAIDS 2018;78:589-98

BIC/FTC/TAF vs DTG/ABC/3TC

Study GS-US-380-1489: BIC/F/TAF QD vs DTG/ABC/3TC QD
Gallant J. Lancet. 2017 Nov 4;390(10107):2063-2072 ; Wohl DA Lancet HIV 2019 ; 6:e355-63

BIC/FTC/TAF vs DTG + FTC/TAF

Study GS-US-380-1490: BIC/F/TAF QD vs DTG + F/TAF QD
Sax PE. Lancet. 2017 Nov 4;390(10107):2073-2082; Stellbrink HJ. Lancet HIV 2019 ; 6:e364-72

INSTI vs EFV

RAL + FTC/TDF vs EFV + FTC/TDF

STARTMRK Study: raltegravir vs efavirenz, in combination with TDF/FTC
Lennox JL. Lancet. 2009 Sep 5;374(9692):796-806 ; Rockstroh JK. J Acquir Immune Defic Syndr. 2013 May 1;63(1):77-85.

EVG/C/FTC/TDF vs EFV/FTC/TDF

Study GS-US-236-0102: EVG/c/FTC/TDF QD vs EFV/FTC/TDF QD
Sax PE. Lancet. 2012 Jun 30;379(9835):2439-48. ; Zolopa A. J Acquir Immune Defic Syndr. 2013 May 1;63(1):96-100. ; Wohl DA. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e118-20.

DTG + ABC/3TC vs EFV/FTC/TDF

SINGLE Study: DTG + ABC/3TC vs TDF/FTC/EFV QD
Walmsley SL. N Engl J Med. 2013 Nov 7;369(19):1807-18; JAIDS 2015; 70:515-9; ICAAC 2012. Abs.H556b ; Pappa K. ICAAC 2014, Abs. H-647a ; Tebas P. AIDS 2015; 29:2459-64

DTG + TAF/FTC vs DTG + TDF/FTC vs EFV/TDF/FTC

ADVANCE Study: DTG + TAF/FTC vs DTG + TDF/FTC vs EFV/TDF/FTC in first-line
Venter WDF, N Engl J Med. 2019;381:803-15 ; Venter WDF, IAS 2019, WEAB0405LB ; Hill A, IAS 2019, MOAX0102LB

INSTI vs PI

DTG + 2NRTI vs DRV/R + 2 NRTI

FLAMINGO Study: DTG QD + 2 NRTI vs DRV/r QD + 2 NRTI
Clotet B. Lancet. 2014 Jun 28;383(9936):2222-31

EVG/C/FTC/TDF vs ATV/r + FTC/TDF

Study GS-236-0103: EVG/c/FTC/TDF QD vs ATV/r + FTC/TDF QD
DeJesus E. Lancet. 2012 Jun 30;379(9835):2429-38. ; Rockstroh JK. J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):483-6. ; Clumeck N. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e121-4

ATV/r + FTC/TDF vs DRV/r + FTC/TDF vs RAL + FTC/TDF

ACTG A5257 Study: (ATV/r vs DRV/r vs RAL) + TDF/FTC
Lennox JL. Ann Intern Med. 2014 Oct 7;161(7):461-71 ; Ofotokun I. Clin Infect Dis. 2015 Jun 15;60(12):1842-51 ; Brown TT. J Infect Dis. 2015 Oct 15;212(8):1241-9 ; Mc Comsey GA. CROI 2015, Abs. 140 ; Kelesidis T. Clin Infect Dis. 2015 Aug 15;61(4):651-60

EVG/C/FTC/TDF QD vs ATV/r + FTC/TDF

Study WAVES : EVG/C/FTC/TDF QD vs ATV + r + FTC/TDF QD in Women
Squires K. IAS 2015 Vancouver, Abs. MOLBPE08 ; Lancet HIV 2016; 3(9):e410-e420

DTG/ABC/3TC vs ATV/rFTC/TDF

Study ARIA : DTG/ABC/3TC QD vs ATV + r + FTC/TDF QD in Women
Orrell C. Lancet HIV 2017 4:e536-46

Intensification with INSTI

EFV + 2 NRTI vs EFV + 2 NRTI + RAL

REALITY Study: raltegravir -intensified quadruple therapy in first-line antiretroviral therapy
Kityo C .PLoS Med. 2018 ; 15(12):e1002706

2 drugs vs 3 drugs

LPV/r + 3TC vs LPV/r + 2 NRTI

GARDEL Study: LPV/r + 3TC vs LPV/r + 2 NRTI
Cahn P. Lancet Infect Dis. 2014 Jul;14(7):572-80

DRV/r + 3TC vs DRV/r + 3TC/TDF

DUAL Study: switch to DRV/r + 3TC
Pulido F. Clin Infect Dis 2017; 65:2112-8

DTG + 3TC vs DTG + FTC/TDF

GEMINI 1 & 2 Studies: DTG + 3TC vs DTG + TDF/FTC in first-line
Cahn P. Lancet. 2019; 393:143-55 IAS 2019, Abs. WEAB0404LB ; Van Wyk J. IDWeek 2019, Abs. 2842; Orkin C JIAS 2018;21,suppl. 8:31; Eron J. HIV DART and Emerging Viruses 2018; Miami, OP #7; Underwood M, CROI 2019, Abs. 490

NRTI-Sparing

ATV + RAL vs ATV/r + FTC/TDF

SPARTAN Study: ATV + RAL BID vs ATV/r + TDF/FTC QD
Kozal MJ. HIV Clin Trials. 2012 May-Jun;13(3):119-30

LPV/r + RAL vs LPV/r + FTC/TDF

PROGRESS Study: LPV/r + RAL vs LPV/r + TDF/FTC
Reynes J. HIV Clin Trials. 2011 Sep-Oct;12(5):255-67; AIDS Res Hum Retroviruses. 2013 Feb;29(2):256-65

DRV/r + RAL vs DRV/r + FTC/TDF

Study NEAT 001/ANRS 143: DRV/r + RAL vs DRV/r + TDF/FTC
Bernardino JI. Lancet HIV. 2015 Nov;2(11):e464-73 ; Lambert-Niclot S. JAC 2015 (in press) ; Raffi F. Lancet 2014; 384:1942-51.

RADAR Study: DRV/r + RAL vs DRV/r + TDF/FTC
Bedimo RJ. PLoS One. 2014 Aug 29;9(8):e106221

ATV/r + MVC vs LPV/r + FTC/TDF

A4001078 Study: ATV/r + MVC vs ATV/r + TDF/FTC
Mills A. J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):164-70

LPV/r + MVC vs LPV/r + FTC/TDF

VEMAN Study: LPV/r + MVC vs LPV/r + TDF/FTC
Nozza S. Clin Microbiol Infect. 2015 May;21(5):510

DRV/r + MVC vs DRV/r + FTC/TDF

MODERN Study: MVC QD + DRV/r vs TDF/FTC + DRV/r
Stellbrink HJ. AIDS 2016; 30:1229-38

Switch studies in virologically suppressed patients

Switch ABC/3TC to TDF/FTC

ABC/3TC vs FTC/TDF

SWIFT Study
Campo R. Clin Infect Dis. 2013 Jun;56(11):1637-45

ABC/3TC vs FTC/TAF

GS-US-1717 Study : Switch ABC/3TC to TAF/FTC
Winston A. Lancet HIV.2018 ; 5:e162-71

Switch TDF to TAF

E/C/F/TAF

GS-US-292-0109 Study
Mills A. Lancet Infect Dis. 2016 Jan;16(1):43-52 & IAS 2015, Abs. TUAB0102 ; DeJesus E. ASM Microbe 2016, Abs. LB-087

FTC/TDF vs FTC/TAF

GS-US-311-1089 Study
Gallant J. CROI 2016, Abs. 29 & Lancet HIV. 2016;3:e158-65 ; Raffi F. J Acquir Immune Defic Syndr. 2017;75:226-31

RPV/FTC/TDF vs RPV/FTC/TAF

GS-US-366-1216 Study : Switch RPV/FTC/TDF to RPV/FTC/TAF
Orkin C. Lancet HIV 2017 ; 4:e195-204

EFV/FTC/TDF vs RPV/FTC/TAF

GS-US-366-1160 Study : Switch EFV/FTC/TDF to RPV/FTC/TAF
De Jesus E. Lancet HIV 2017; 4:e205-13

Switch PI to NNRTI

FTC + ddI + EFV

ALIZE Study
Molina JM. J Infect Dis. 2005 Mar 15;191(6):830-9

EFV/FTC/TDF

AI266073 Study
De Jesus E. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):163-74

RPV/FTC/TDF

SPIRIT Study
Paella FJ. Jr AIDS. 2014 Jan 28;28(3):335-44

ETR + 2 NRTI

Etraswitch Study
Echeverria P. PLoS One. 2014 Feb 4;9(2):e84676

Switch NNRTI to NNRTI

EFV/FTC/TDF

AI266073 Study
De Jesus E. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):163-74

EFV vs ETR

Switch EFV to ETR: CNS toxicity
Waters L. AIDS. 2011 Jan 2;25(1):65-71

Switch EFV to ETR: Patient's preference
Nguyen A. AIDS. 2011 Jan 2;25(1):57-63

Switch to DOR/3TC/TDF

DRIVE-SHIFT Study: Switch to DOR/3TC/TDF
Johnson M. J Acquir Immune Defic Syndr. 2019 Apr 11. [Epub ahead of print]

Switch to ATV or ATV-r

ATV/r + 2 NRTI vs LPV/r + 2 NRTI

ATAZIP
Mallolas J. J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36

ATV + 2 NRTI or ATV/r + 2 NRTI vs LPV/r + 2 NRTI

SWAN
Gatell JM. Clin Infect Dis. 2007 Jun 1;44(11):1484-92

SLOAT
Soriano V. J Antimicrob Chemother. 2008 Jan;61(1):200-5

ATV + ABC/3TC vs ATV/r + ABC/3TC

ARIES
Squires KE. AIDS. 2010 Aug 24;24(13):2019-27 & IAS 2011; Abs. MOPE215

ATV/r + 2 NRTI vs ATV/r + 2 NRTI

INDUMA
Ghosn J. Antivir Ther. 2010;15(7):993-1002

ATV + ABC/3TC vs ATV/r + FTC/TDF

ASSURE
Wohl D. PLoS One. 2014 May 13;9(5):e96187.

Switch to PI/r reduced dose

DRV 600/r + 2 NRTI vs DRV 800/r + 2 NRTI

DRV600 Study
Molto J. J AntimicrobChemother 2015;70:1139-45

ATV 200/r + 2NRTI vs ATV 300/r + 2 NRTI

LASA Study: switch to ATV/r 200/100 vs 300/100 mg QD
Bunupuradah T. Lancet HIV 2016;3:e343-50

Switch to PI/r monotherapy

HIV-NAT 077 Study: Switch double PI/r to LPV/r monotherapy
Bunupuradah T. AIDS. 2011 Jan 28;25(3):315-23

Switch to LPV/r monotherapy
Cahn P. EACS 2009; Abs. PS4/3

Pilot Study: Switch to LPV/r monotherapy
Pierone G. HIV Clin Trials. 2006 Sep-Oct;7(5):237-45

OREY
Pulido F. EACS 2009;Abs. PS4/6

ACTG A5201
Wilkin TJ. J Infect Dis. 2009 Mar 15;199(6):866-71

Swedish study
Karlström O. J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):417-22

ATARITMO
Vernazza P. AIDS. 2007 Jun 19;21(10):1309-15

LPV/r mono vs EFV + ZDV/3TC

M03-613 Study: Switch to LPV/r monotherapy
Cameron DW. J Infect Dis. 2008 Jul 15;198(2):234-40

LPV/r mono

MOST Study: Switch to LPV/r monotherapy
Gutmann C. AIDS. 2010 Sep 24;24(15):2347-54

KALESOLO Study: Switch to LPV/r monotherapy
Meynard JL. J Antimicrob Chemother. 2010 Nov;65(11):2436-44

KalMo Study: Switch to LPV/r monotherapy
Nunes EP. HIV Clin Trials. 2009 Nov-Dec;10(6):368-74

LPV/r mono vs LPV/r + 2 NRTI

OK04 Study: Switch LPV/r + 2NRTIs to LPV/r monotherapy
Pulido F. AIDS. 2008 Jan 11;22(2):F1-9 ; Arribas JR. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):147-52

OK Study: Switch LPV/r + 2NRTIs to LPV/r monotherapy
Arribas JR. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):280-7

ATV/r mono vs ATV/r + 2 NRTI

MODAt
Castagna A. AIDS. 2014 Sep 24;28(15):2269-79 ; Galli L. J Antimicrob Chemother. 2016 Jun;71(6):1637-42

DRV/r mono vs DRV/r + 2 NRTI

PROTEA Study: Switch PI or NNRTI to DRV/r QD monotherapy
Antinori A. AIDS. 2015 Sep 10;29(14):1811-20

MONET Study: Switch PI or NNRTI to DRV/r qd monotherapy
Arribas JR. AIDS. 2010 Jan 16;24(2):223-30 & HIV Med. 2012 Aug;13(7):398-405 ; Rieger A, et al. AIDS 2010; Abs. THLBB209

MONOI Study: Switch to DRV/r bid monotherapy
Katlama C. AIDS. 2010 Sep 24;24(15):2365-74 ; Marcelin AG. CROI 2011; Abs.533

PI/r mono

PIVOT Study
Paton NI. Lancet HIV. 2015 Oct;2(10):e417-26

LPV/r mono vs LPV/r + 3TC or DRV/r mono or DRV/r + 3TC

MOBIDIP Study
Ciaffi L. Lancet HIV 2017; 4:e384-92

Switch to RAL-containing regimen

Canadian Study: Switch ENF to RAL
M. Harris AIDS. 2008 Jun 19;22(10):1224-6

CHEER Study: Switch ENF to RAL
Towner W. J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):367-73

Montreal Study : Switch ENF to RAL
Talbot A. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):362-4

RAL vs ENF

EASIER Study: Switch ENF to RAL
De Castro N. Clin Infect Dis. 2009 Oct 15;49(8):1259-67 ; Gallien S. J Antimicrob Chemother. 2011 Sep;66(9):2099-106 ; Silva EF. J Infect Dis. 2013 Sep;208(6):892-7

RAL vs LPV/r

SWITCHMRK Study: Switch to RAL vs continuation of LPV/r
Eron JJ. Lancet. 2010 Jan 30;375(9712):396-407

RAL vs IP/r

SPIRAL Study: Switch PI/r to RAL
Martinez E. AIDS. 2010;24(11):1697-707; AIDS. 2012;26(18):2315-26; AIDS Res Hum Retroviruses. 2013;29(2):235-41 ; Curran A. AIDS. 2012;26(4):475-81 ; Saumoy M. Atherosclerosis. 2012;225(1):200-7 ; Masiá M. J Antimicrob Chemother. 2013;68(2):409-13

RAL + 2 NRTI vs EFV + 2 NRTI

Switch-ER Study: Switch EFV to RAL
Nguyen A. AIDS. 2011 Jul 31;25(12):1481-7

Switch to DTG-containing regimen

DTG monotherapy

EARLY-SIMPLIFIED Study: DTG monotherapy for maintenance
Braun DL, Clin Infect Dis 2019, Janv 2, Epub ahead of print

MONCAY Study: DTG monotherapy for maintenance
Hocqueloux L, Clin Infect Dis 2019 ; Janv 2 , Epub ahead of print

DOMONO Study: Switch to dolutegravir monotherapy
Wijting I. Lancet HIV 2017; 4:e547-54; J Infect Dis. 2018 ;218:688-97

DTG /ABC/3TC vs 2 NRTI + 3rd agent

STRIIVING Study
Trottier B. Antivir Ther. 2017;22(4):295-305

DTG + FTC/TDF or ABC/3TC vs IP/r + FTC/FDT vs ABC/3TC

NEAT 022 Study: Switch to DTG vs continuation of PI/r in patients with high cardiovascular risk
Gatell JM. AIDS 2017;31:2503-14 ; Gatell JM. Clin Infect Dis 2019 ; 68 :597-606

DTG + 3TC

TANGO Study: switch to DTG/3TC
Van Wyk J. Clin Infect Dis 2020 Jan 6 (Epub ahead of print]

ASPIRE Study: switch to DTG + 3TC
Taiwo B. Clin Infect Dis. 2018 May 17;66(11):1794-1797

Switch to E/C/FTC/TDF

EVG/C/F/TDF vs NNRTI + FTC/TDF

STRATEGY-NNRTI Study: Switch NNRTI to EVG/c
Pozniak A. Lancet Infect Dis. 2014 Jul;14(7):590-9

EVG/C/F/TDF vs PI/r + FTC/TDF

STRATEGY-PI Study: Switch PI/r to EVG/c
Arribas JR. Lancet Infect Dis. 2014 Jul;14(7):581-9

Switch to E/C/F/TAF

GS-US-292-0109 Study
Mills A. Lancet Infect Dis. 2016 Jan;16(1):43-52 & IAS 2015, Abs. TUAB0102 ; DeJesus E. ASM Microbe 2016, Abs. LB-087

GS-US-292-0112 Study
Pozniak A. JAIDS 2016;71:530-7

Switch to E/C/F/TAF + DRV/r

GS-US-292-0119 Study
Huhn GD. JAIDS 2017; 74:193.200

Switch to BIC/FTC/TAF

BIC/FTC/TAF vs ATV/r or ATV/c or DRV/r or DRV/c + ABC/3TC or FTC/TDF

GS-US-380-1878 Study: Switch to BIC/FTC/TAF
Daar ES. Lancet 2018;5:e347-56

BIC/FTC/TAF vs DTG/ABC/3TC

GS-US-380-1844 Study: Switch to BIC/FTC/TAF
Molina JM. Lancet 2018;5:e357-65

BIC/FTC/TAF vs E/C/F/TDF or E/C/F/TAF or ATV/r + FTC/TDF

GS-US-380-1961 Study : Switch to BIC/FTC/TAF
Kityo C CROI 2018, Abs. 500

Switch to INSTI + NNRTI

DTG + RPV

SWORD Study: Switch to DTG + RPV
Llibre JM. Lancet. 2018 ; 391:839-49

CAB LA + RPV LA IM

ATLAS Study: LA cabotegravir + rilpivirine for maintenance
Swindells S. CROI 2019, Abs. 139; Murray M, IAS 2019, Abs. MOAB0103

FLAIR Study: LA cabotegravir + rilpivirine for maintenance
Orkin C. CROI 2019, Abs. 140LB; Murray M, IAS 2019, Abs. MOPEB258

LATTE-2 Study: Switch to cabotegravir LA + rilpivirine LA IM
Margolis DA. Lancet. 2017 Sep 23;390(10101):1499-1510.

Switch to RAL + PI/r

RAL + ATV/r vs ATV/r + FTC/TDF

HARNESS Study
Van Lunzen J. JAIDS 2016;71:538-43 & IAC 2014, Melbourne, Abs. LBPE19

RAL + LPV/r

KITE Study
Ofotokun J. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1196-206

RAL + DRV/r vs LPV/r + FTC/TDF

SPARE Study
Nishijima T. PLoS One. 2013 Aug 8;8(8)

Switch to PI/r + 3TC

ATV/r + 3TC vs ATV/r + 2 NRTI

SALT Study
Perez-Molina JA. Lancet Infect Dis 2015; 15:775-84 & JAC 2017; 72:246-53

ATLAS-M Study
Di Giambenedetto S. J Antimicrob Chemother 2017;72:1163-1171

LPV/r + 3TC vs LPV/r + 2 NRTI

OLE Study
Arribas JR. Lancet Infect Dis 2015; 2015; 15:785-92

Switch to DRV/r + RPV

PROBE Study
Maggiolo F. J Acquir Immune Defic Syndr. 2016 May 1;72(1):46-51

Switch to D/C/F/TAF

D/C/F/TAF vs IP/r + FTC/TDF

EMERALD Study
Orkin C. Lancet HIV. 2018 Jan;5(1):e23-e34.

Switch to MVC

MVC + 2 NRTI vs MVC + PI/r vs PI/r + 2 NRTI

MARCH Study
Pett SL. Clin Infect Dis 2016;63:122-32

Phase 2 of new ARVs

Fostemsavir, prodrug of temsavir (attachment inhibitor)

FOS + RAL + TDF vs ATV/r + RAL + TDF

AI438011 Study : Fostemsavir Phase II
Lalezari J. Lancet HIV 2015; 2:e427-37 ; Thompson M. CROI 2015, Abs. 545

TAF (TFV prodrug)

E/C/F/TAF vs E/C/F/TDF

Study 292-0102 : EVG/c/FTC/TAF QD vs EVG/c/FTC/TDF QD (Phase 2)
Sax PE. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):52-8

D/C/F/TAF vs D/C + FTC/TDF

Study GS-US-299-0102: D/C/F/TAF QD STR vs DRV + COBI + F/TDF QD
Mills A. JAIDS 2015; 69: 439-45

Doravirine (non nucleoside reverse transcriptase inhibitor)

DOR + FTC/TDF vs EFV/FTC/TDF

MK1439007 : doravirine (DOR) + TDF/FTC vs EFV + TDF/FTC
Morales-Ramirez JO. CROI 2014, Abs. 92LB ; Gatell JM. HIV Drug Therapy 2014, Abs. O434

Cabotegravir (integrase inhibitor)

CAB LA + RPV LA

LATTE Study : cabotegravir Phase II
Margolis DA. Lancet Infect Dis 2015; 15:1145-55

Bictegravir

BIC +/FTC/TAF vs DTG + FTC/TAF

BIC Phase 2 Study: BIC + FTC/TAF vs DTG + FTC/TAF
Sax PE. Lancet HIV 2017; 4:e154-e160

Islatravir (ISL)

DRIVE2Simplify Study: Islatravir + Doravirine Phase 2
Molina JM, IAS 2019, Abs. LBPED46, Abs. WEAB0402LB

THE MOST COMPLETE WEBSITE ON CLINICAL TRIALS IN HIV INFECTION (FIRST-LINE, SWITCH, PHASE 2)

Head-to-head comparative trials for first line ART since 2006

NRTI combinations

ZDV/3TC + EFV vs TDF + FTC + EFV

ABC/3TC + LPV/r vs FTC/TDF + LPV/r

ABC/3TC + EFV or ATV/r vs FTC/TDF + EFV or ATV/r

ABC/3TC + EFV vs FTC/TDFC + EFV

FTC/TDF vs FTC/TAF or E/C/F/TDF vs E/C/F/TAF

D/C/F/TAF vs D/C + FTC/TDF

DTG + TAF/FTC vs DTG + TDF/FTC vs EFV/TDF/FTC

NNRTI vs NNRTI

EFV 600 + FTC/TDF vs EFV 400 + FTC/TDF

EFV + FTC/TDF or 2 NRTI vs RPV + FTC/TDF or 2 NRTI

RPV/FTC/TDF vs EFV/FTC/TDF

EFV + 2 NRTI vs ETR + 2 NRTI

EFV/FTC/TDF vs DOR/3TC/TDF

NNRTI vs PI/r

EFV + 2 NRTI vs LPV/r + 2NRTI vs EFV + LPV/r

EFV + ZDV/3TC vs LPV/r + ZDV/3TC

NVP + FTC/TDF vs ATV/r + FTC/TDF

ABC/3TC + EFV or ATV/r vs FTC/TDF + EFV or ATV/r

DOR + 2 NRTI vs DRV/r + 2 NRTI

EFV vs MVC

EFV + ZDV/3TC vs MVC + ZDV/3TC

PI vs PI

ATV + 3TC + d4T vs ATV/r + 3TC + d4T

LPV/r mono vs LPV/r + ZDV/3TC

LPV/r QD + FTC + TDF vs LPV/r BID + FTC + TDF

LPV/r QD + FTC + d4T or TDF vs LPV/r BID + FTC + d4T or TDF

TITRE%31%

ATV/r + FTC/TDF vs FPV/r + FTC/TDF

ATV/r + FTC/TDF vs DRV/r + FTC/TDF

FPV/r + ABC/3TC vs LPV/r + ABC/3TC

SQV/r + FTC/TDF vs LPV/r + FTC/TDF

ATV/r + FTC/TDF vs LPV/r + FTC/TDF

DRV/r + FTC/TDF vs LPV/r + FTC/TDF

DRV/r + 3TC vs DRV/r + 3TC/TDF

RTV vs Cobi

ATV/r + FTC/TDF vs ATV/c + FTC/TDF

INSTI vs INSTI

RAL QD + FTC/TDF vs RAL BID + FTC/TDF

DTG QD + 2 NRTI vs RAL BID + 2 NRTI

RAL 1200 QD vs 400 BID + FTC/TDF

BIC/FTC/TAF vs DTG/ABC/3TC

BIC/FTC/TAF vs DTG + FTC/TAF

INSTI vs EFV

RAL + FTC/TDF vs EFV + FTC/TDF

EVG/C/FTC/TDF vs EFV/FTC/TDF

DTG + ABC/3TC vs EFV/FTC/TDF

DTG + TAF/FTC vs DTG + TDF/FTC vs EFV/TDF/FTC

INSTI vs PI

DTG + 2NRTI vs DRV/R + 2 NRTI

EVG/C/FTC/TDF vs ATV/r + FTC/TDF

ATV/r + FTC/TDF vs DRV/r + FTC/TDF vs RAL + FTC/TDF

EVG/C/FTC/TDF QD vs ATV/r + FTC/TDF

DTG/ABC/3TC vs ATV/rFTC/TDF

Intensification with INSTI

EFV + 2 NRTI vs EFV + 2 NRTI + RAL

2 drugs vs 3 drugs

LPV/r + 3TC vs LPV/r + 2 NRTI

DRV/r + 3TC vs DRV/r + 3TC/TDF

DTG + 3TC vs DTG + FTC/TDF

NRTI-Sparing

ATV + RAL vs ATV/r + FTC/TDF

LPV/r + RAL vs LPV/r + FTC/TDF

DRV/r + RAL vs DRV/r + FTC/TDF

ATV/r + MVC vs LPV/r + FTC/TDF

LPV/r + MVC vs LPV/r + FTC/TDF

DRV/r + MVC vs DRV/r + FTC/TDF

Switch studies in virologically suppressed patients

Switch ABC/3TC to TDF/FTC

ABC/3TC vs FTC/TDF

ABC/3TC vs FTC/TAF

Switch TDF to TAF

E/C/F/TAF

FTC/TDF vs FTC/TAF

RPV/FTC/TDF vs RPV/FTC/TAF

EFV/FTC/TDF vs RPV/FTC/TAF

Switch PI to NNRTI

FTC + ddI + EFV